This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Histologic changes after H.pylori eradication with Killing Hp decoction for chronic gastritis
Na Wang, Xi-Xian Yao, Lin Zhang, Wen-Yuan Bai, Li-Ying Feng
Na Wang, Xi-Xian Yao, Lin Zhang, Wen-Yuan Bai, Li-Ying Feng, The 2nd Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Correspondence to: Dr. Xi-Xian Yao, The 2nd Hospital of Hebei Medical University, 215 Heping Xi Lu, Shijiazhuang 050000, Hebei Province, China.email@example.com
Received: July 1, 2002 Revised: July 20, 2002 Accepted: July 25, 2002 Published online: May 15, 2003
To study the histologic changes after H.pylori eradication with Killing Hp decoction for chronic gastritis.
Total 81 cases of chronic gastritis with H.pylori infection were prospectively studied. After a 7-day triple therapy (bismuth potassium citrate, clarithromycin and tinidazole), the patients were divided randomly into 3 groups. Group A (n = 23): Killing Hp decoction, 1 Bid; GroupB (n = 15): marzulene-s-granules, 1 Tid; Group C (n = 15): aluminium hydroxide compound, 3-5 Bid; An endoscopy was performed at the frist and third months. Histological changes of gastric mucosa were compared before and after the treatment according to Sydney classification. COX-2(cyclooxygenase-2) protein was detected by immunohistochemical method, and the computer image processing system was used. For the patients of no eradication after one course therapy, anti-H.pylori treatment continued.
H.pylori eradication got a very good curative effect in 81.9% of the patients. A favourable histologic change of acute inflammatory infiltration was found (average values from 0.79±0.78 to 0.042±0.14) (P<0.001).The mean percentage of COX-2 positive cells significantly decreased after H.pylori eradication [(43.5±12.3)%, (32.3±8.3)%, P<0.001]. No chronic inflammation was observed after one month therapy (1.90±0.68, 1.67±0.76, P>0.05. Compared to the controls, after Killing Hp decoction treatment for three months, the score corresponding to chronic gastritis declined progressively (average values from 2.9±0.6 to 1.30±0.60, P<0.001), and the mean percentage of COX-2 positive cells staining got further decreased and reached a statistically significant difference, compared with the results obtained at the first month. [(31.6±5.9)%, (27.09±5.16)%, P<0.05]. Gastric atrophic lesions were improved after "killing Hp decoction" for three-month treatment.
H. pylori related gastritis should be treated further with Killing Hp decoction after H.pylori eradication.
Key Words: N/A
Citation: Wang N, Yao XX, Zhang L, Bai WY, Feng LY. Histologic changes after H.pylori eradication with Killing Hp decoction for chronic gastritis. Shijie Huaren Xiaohua Zazhi 2003; 11(5): 558-561
Chen XY, van der Hulst RW, Bruno MJ, van der Ende A, Xiao SD, Tytgat GN, Ten Kate FJ. Interobserver variation in the histopathological scoring of H.pylori related gastritis.J Clin Pathol. 1999;52:612-616.
Savarino V, Mela GS, Zentilin P, Lapertosa G, Bisso G, Mele MR, Pivari M, Mansi C, Vigneri S, Celle G. Histological and functional recovery in patients with multifocal atrophic gastritis after eradication of Helicobacter pylori infection.Ital J Gastroenterol Hepatol. 1999;31:4-8.
Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy.J Natl Cancer Inst. 2000;92:1881-1888.
Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.Gastroenterology. 2000;119:7-14.
Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, Luckers AE, Klinkenberg-Knol EC, Festen HP, Viergever PP. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.Gut. 2000;46:615-621.
Gisbert JP, Blanco M, Pajares JM. Effect of Helicobacter pylori eradication on histological lesions of gastric mucosa. An 18-month follow-up study.Rev Clin Esp. 2000;200:480-484.
Basso D, Gallo N, Zambon CF, Baron M, Navaglia F, Stockreiter E, Di Mario F, Rugge M, Plebani M. Antigastric autoantibodies in Helicobacter pylori infection: role in gastric mucosal inflammation.Int J Clin Lab Res. 2000;30:173-178.
Ruiz B, Garay J, Correa P, Fontham ET, Bravo JC, Bravo LE, Realpe JL, Mera R. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection.Am J Gastroenterol. 2001;96:3281-3287.
Mones J, Rodrigo L, Sancho F, Martin L, Boixeda D, Artes MT, Garcia-Cases C. Club Espanol parael Estudio del Helicobacter pylori . Helicobacter pylori eradication versus one-year maintenance therapy: effect on relapse and gastritis outcome.Rev Esp Enferm Dig. 2001;93:372-389.
Tepes B, Kavcic B, Zaletel LK, Gubina M, Ihan A, Poljak M, Krizman I. Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication.J Pathol. 1999;188:24-29.
Zerbib F, Lenk C, Sawan B, Cayla R, Broutet N, Carles B, de Mascarel A, Megraud F, Lamouliatte H. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients.Eur J Gastroenterol Hepatol. 2000;12:719-725.
Annibale B, Aprile MR, D mbra G, Caruana P, Bordi C, Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia.Aliment Pharmacol Ther. 2000;14:625-634.
Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.Ann Intern Med. 2001;134:380-386.
Chan FK, To KF, Ng YP, Lee TL, Cheng AS, Leung WK, Sung JJ. Expression and cellular localization of COX-1 and COX-2 in Helicobacter pylori gastritis.Aliment Pharmacol Ther. 2001;15:187-193.
Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FK. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions.Am J Pathol. 2000;157:729-735.
Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ, Wilson KT. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis.Gastroenterology. 1999;116:1319-1329.
Zarrilli R, Tuccillo C, Santangelo M, Nardone G, Romano M. Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis.Am J Gastroenterol. 1999;94:3376-3378.
Kimura A, Tsuji S, Tsujii M, Sawaoka H, Iijima H, Kawai N, Yasumaru M, Kakiuchi Y, Okuda Y, Ali Z. Expression of cyclooxygenase -2 and nitrotyrosine in human gastric mucosa before and after H.pylori eradication.Prostagl Leukot Essent Fatty Acids. 2000;63:315-322.
McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection.Am J Gastroenterol. 1999;94:1218-1223.